In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
Health advancements made at OMRF could translate to better health for your pets.
The project is focused on lupus, which affects up to 1.5 million Americans.
Agreement will expand clinical trials of glioblastoma drug